X
X
Total 667546 Results
| Label | Description | ILX | Version | Created CID | Modified Time | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Basilea Pharmaceutica | A Switzerland-based company formed as a spin-off entity from the drug giant Hoffmann–La Roche that develops and commercializes pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections, and oncology, targeting the medical challenge of rising resistance and nonresponse to current treatment options. | ILX:0101120 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Basiliximab | A recombinant chimeric (murine/human) monoclonal antibody (IgG1k) that functions as an immunosuppressive agent, specifically binding to and blocking the interleukin-2 receptor a-chain (IL-2R alpha, also known as CD25 antigen) on the surface of activated T-lymphocytes. It is a 144 kDa glycoprotein obtained from fermentation of an established mouse myeloma cell line genetically engineered to express plasmids containing the human heavy and light chain constant region genes and mouse heavy and light chain variable region genes encoding the RFT5 antibody that binds selectively to the IL-2R alpha. Pharmacology: Simulect functions as an IL-2 receptor antagonist. Specifically it inhibits IL-2-mediated activation of lymphocytes, a critical pathway in the cellular immune response involved in allograft rejection. Mechanism of action: Simulect binds with high-affinity to the Tac subunit of the high-affinity IL-2 receptor complex and inhibits IL-2 binding. The IL-2 receptor (Tac) subunit is expressed on activated but not resting lymphocytes. Drug type: Approved. Biotech. Investigational. Drug category: Immunomodulatory Agents. Immunosuppressive Agents | ILX:0101121 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Basis modioli | ILX:0101122 | 10 | scicrunch | 06/23/2020 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Basket Cell Morphology | ILX:0101123 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Basolateral amygdalar nucleus anterior part of ABA 2009 | ILX:0101124 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Basolateral amygdalar nucleus of ABA 2009 | ILX:0101125 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Basolateral amygdalar nucleus posterior part of ABA 2009 | ILX:0101126 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Basolateral amygdalar nucleus ventral part of ABA 2009 | ILX:0101127 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Basolateral nuclear complex | A set of amygdalar nuclei comprising the lateral nucleus (LA), the basal nucleus (BA), and the accessory basal nuclei (ABN). These nuclei are bordered laterally by the external capsule and medially by the central amygdalar nucleus as well as the amygdalohippocampal area. This definition refers to the rat Basolateral nuclear complex. | ILX:0101128 | 11 | scicrunch | 06/23/2020 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Basomedial amygdalar nucleus anterior part of ABA 2009 | ILX:0101129 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Basomedial amygdalar nucleus of ABA 2009 | ILX:0101130 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Basomedial amygdalar nucleus posterior part of ABA 2009 | ILX:0101131 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Basommatophora | ILX:0101132 | 6 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Batrachia | ILX:0101133 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Battery | ILX:0101134 | 5 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Bay ghost shrimp | ILX:0101135 | 5 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Bayer HealthCare Pharmaceuticals | A research-based pharmaceutical company that is the pharmaceuticals operation of Bayer HealthCare LLC, a division of Bayer AG. Bayer HealthCare combines the global activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions. In the United States, Bayer HealthCare Pharmaceuticals is comprised of the following business units: Women's Healthcare, Diagnostic Imaging, General Medicine, Hematology / Neurology and Oncology. They aim to discover and manufacture products that will improve human health worldwide by diagnosing, preventing and treating diseases. | ILX:0101136 | 5 | scicrunch | 08/24/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| BB1 receptor | ILX:0101137 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| BB2 receptor | ILX:0101138 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| BB3 receptor | ILX:0101139 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
About
Base community for the SciCrunch.org infrastructure
Contact Us
X